Lineage Cell Therapeutics, Inc. Deferred Tax Liabilities, Gross
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Liabilities, Gross of $14.33 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-05
- 2025-12-31: Deferred Tax Liabilities, Gross $14.33M.
- 2024-12-31: Deferred Tax Liabilities, Gross $7.39M.
- 2023-12-31: Deferred Tax Liabilities, Gross $5.00M.
- 2022-12-31: Deferred Tax Liabilities, Gross $2.58M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $14.33M 10-K · filed 2026-03-05 |
| 2024-12-31 | $7.39M 10-K · filed 2026-03-05 |
| 2023-12-31 | $5.00M 10-K · filed 2025-03-10 |
| 2022-12-31 | $2.58M 10-K · filed 2024-03-07 |
| 2021-12-31 | $14.20M 10-K · filed 2023-03-09 |
| 2020-12-31 | $15.90M 10-K · filed 2022-03-10 |
| 2014-06-30 | $4.70M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |